Atara Biotherapeutics, Inc. (ATRA) Receives $25.75 Consensus Target Price from Analysts
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $25.75.
A number of equities analysts have commented on ATRA shares. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. ValuEngine downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Finally, Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a report on Monday, August 7th.
Shares of Atara Biotherapeutics (ATRA) traded down 2.20% during mid-day trading on Tuesday, reaching $13.35. 176,322 shares of the company traded hands. The firm has a 50 day moving average of $14.97 and a 200-day moving average of $15.91. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.40. The stock’s market capitalization is $407.96 million.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05. On average, equities research analysts expect that Atara Biotherapeutics will post ($3.96) EPS for the current fiscal year.
In other news, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00. Following the sale, the executive vice president now owns 368,080 shares in the company, valued at $4,656,212. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 2,800 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $16.94, for a total value of $47,432.00. Following the sale, the chief executive officer now owns 731,859 shares in the company, valued at approximately $12,397,691.46. The disclosure for this sale can be found here. Insiders sold 52,059 shares of company stock valued at $752,211 over the last quarter. 16.10% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of ATRA. State Street Corp raised its stake in shares of Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock worth $8,526,000 after buying an additional 231,541 shares during the last quarter. Norges Bank purchased a new stake in shares of Atara Biotherapeutics during the fourth quarter worth approximately $4,031,000. Teachers Advisors LLC raised its stake in shares of Atara Biotherapeutics by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 137,416 shares of the biotechnology company’s stock worth $1,951,000 after buying an additional 7,165 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after buying an additional 4,791 shares in the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $829,000. Institutional investors and hedge funds own 78.21% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.